Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: Inhibitor flexibility is a useful design feature for reducing drug resistance

Journal of Molecular Biology

Volumn 284, Issue 2, 1998, Pages 313-323

  Hsiou, Yu ^a   Das, Kalyan ^a   Ding, Jianping ^a   Clark Jr , Arthur D ^a   Kleim, Jörg Peter ^b   Rösner, Manfred ^b   Winkler, Irvin ^b   Riess, Günther ^b   Hughes, Stephen H ^c   Arnold, Edward ^a  

^a RUTGERS UNIVERSITY   (United States)

^b SANOFI   (France)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

AIDS; Drug design; Drug resistance mechanisms; Polymerase structure; X ray crystallography

Indexed keywords

LEUCINE; NEVIRAPINE; PHENYLALANINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TALVIRALINE; TYROSINE;

ARTICLE; BUTTERFLY; CELL CULTURE; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; DRUG PROTEIN BINDING; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTANT; NONHUMAN; PRIORITY JOURNAL;

EID: 13144282707     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.1998.2171     Document Type: Article

References (32)

1. Arnold E., Das K., Ding J., Yadav P.N.S., Hsiou Y., Boyer P.L., Hughes S.H. Targeting HIV reverse transcriptase for anti-AIDS drug design. Drug Des. Disc. 13:1996;29-47
2. Boyer P., Gao H.-Q., Hughes S.H. A mutation at position 190 of HIV-1 RT interacts with mutations at positions 74 and 75 via the template-primer. Antimicrob. Agents Chemother. 42:1998;447-452
3. Brunger A.T. X-PLOR Manual Version 3.1: A System for X-ray Crystallography and NMR. 1993;Yale University Press, New Haven and London
4. Clark A.D. Jr, Jacobo-Molina A., Clark P., Hughes S.H., Arnold E. Crystallization of human immunodeficiency virus type 1 reverse transcriptase with and without nucleic acid substrates, inhibitors and an antibody Fab fragment. Methods Enzymol. 262:1995;171-185
5. The CCP4 suite programs for protein crystallography. Acta Crystallog. sect. D. 50:1994;760-763
6. D'Aquila R.T., Hughes M.D., Johnson V.A., Fischl M.A., Sommadossi J.P., Liou S.H., Timpone J., Myers M., Basgoz N., Niu M., Hirsch M.S. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blinded, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS clinical trials group protocol 241 investigators. Ann. Intern. Med. 124:1996;1019-1030
7. Das K., Ding J., Hsiou Y., Clark A.D. Jr, Moereels H., Koymans L., Andries K., Pauwels R., Janssen P.A.J., Boyer P.L., Clark P., Smith J.R.H., Kroeger, Smith M.B., Michejda C.J., Hughes S.H., Arnold E. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. J. Mol. Biol. 264:1996;1085-1100
8. De Clercq E. HIV resistance to reverse transcriptase inhibitors. Biochem. Pharmacol. 47:1994;155-169
9. De Clercq E. Toward improved anti-HIV chemotherapy therapeutic strategies for intervention with HIV infections. J. Med. Chem. 38:1995;2491-2517
10. Demeter L.M., Meehan P.M., Morse G., Gerondelis P., Dexter A., Berrios L., Cox S., Freimuth W., Reichman R.C. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine. J. AIDS Hum. Retrov. 14:1997;136-144
11. Ding J., Das K., Tantillo C., Zhang W., Clark A.D. Jr, Jessen S., Lu X., Hsiou Y., Jacobo-Molina A., Andries K., Pauwels R., Moereels H., Koymans L., Janssen P.A.J., Smith R., et al. Structure of HIV-1 reverse transcriptase in a complex with the nonnucleoside inhibitor α-APA R 95845 at 2.8 Å resolution. Structure. 3:1995;365-379
12. Ding J., Das K., Moereels H., Koymans L., Andries K., Janssen P.A.J., Hughes S.H., Arnold E. Structure of HIV-1 RT/TIBO R 86183 reveals similarity in the binding of diverse nonnucleoside inhibitors. Nature Struct. Biol. 2:1995;407-415
13. Ding J., Das K., Yadav P.N.S., Hsiou Y., Zhang W., Hughes S.H., Arnold E. A review of HIV-1 RT structural studies and implications for drug design. Veerapandian P. Structure Based Drug Design. 1997;41-82 Marcel Dekker Inc, New York
14. Esnouf R., Ren J., Hopkins A., Ross C., Jones E., Stammers D., Stuart D. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. Proc. Natl Acad. Sci. USA. 94:1997;3984-3989
15. Fan N., Rank K.B., Slade D.E., Poppe S.M., Evans D.B., Kopta L.A., Olmsted R.A., Thomas R.C., Tarpley W.G., Sharma S.K. A drug resistance mutation in the inhibitor binding pocket of human immunodeficiency virus type 1 reverse transcriptase impairs DNA synthesis and RNA degradation. Biochemistry. 35:1996;9737-9745
16. Gulick R.M., Mellors J.W., Havlir D., Eron J.J., Gonzalez C., McMahon D., Richman D.D., Valentine F.T., Jonas L., Meibohm A., Emini E.A., Chodakewitz J.A. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New Engl. J. Med. 337:1997;734-739
17. Hopkins A.L., Ren J., Esnouf R.M., Willcox B.E., Jones E.Y., Ross C., Miyasaka T., Walker R.T., Tanaka H., Stammers D.K., Stuart D.I. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J. Med. Chem. 39:1996;1589-1600
18. Hsiou Y., Ding J., Das K., Clark A.D. Jr, Hughes S.H., Arnold E. Structure of unliganded HIV-1 reverse transcriptase at 2.7 Å resolution implications of conformational changes for polymerization and inhibition mechanisms. Structure. 4:1996;853-860
19. Kleim J., Winkler I., Rosner M., Kirsch R., Rubsamen-Waigmann H., Paessens A., Riess G. In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitor HBY 097. Virology. 28:1997;112-118
20. Kleim J.-P., Bender R., Kirsch R., Meichsner C., Paessens A., Riess G. Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase. Virology. 200:1994;696-701
21. Kleim J.-P., Bender R., Kirsch R., Meichsner C., Paessens A., Roesner M., Ruebsamen-Waigmann H., Kaiser R., Wichers N., Schneweis K.E., Winkler I., Riess G. Preclinical evaluation of HBY 097, a new nonnucleoside reserve transcriptase inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother. 39:1995;2253-2257
22. Kleim J.-P., Roesner M., Winkler I., Paessens A., Kirsch R., Hsiou Y., Arnold E., Riess G. Selective pressure of a quinoxaline class nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT inhibitor specific (RT L74 → V/I, V75 → L/I) HIV-1 mutants. Proc. Natl Acad. Sci. USA. 93:1996;34-38
23. Kohlstaedt L.A., Wang J., Friedman J.M., Rice P.A., Steitz T.A. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science. 256:1992;1783-1790
24. Montaner J.S., Reiss P., Cooper D., Vella S., Harris M., Conway B., Wainberg M.A., Smith D., Robnison P., Hall D., Myers M., Lange J.M. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients the INCAS trial. Italy, the Netherlands, Canada and Australia study. J. Am. Med. Assoc. 279:1998;930-937
25. Nanni R.G., Ding J., Jacobo-Molina A., Hughes S.H., Arnold E. Review of HIV-1 reverse transcriptase three-dimensional structure implications for drug design. Persp. Drug Disc. Des. 1:1993;129-150
26. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:1996;55-62
27. Ren J., Esnouf R., Garman E., Somers D., Ross C., Kirby I., Keeling J., Darby G., Jones Y., Stuart D., Stammers D. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nature Struct. Biol. 2:1995;293-302
28. Ren J., Esnouf R., Hopkins A., Ross C., Jones Y., Stammers D., Stuart D. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO lessons for inhibitor design. Structure. 3:1995;915-926
29. Rodgers D.W., Gamblin S.J., Harris B.A., Ray S., Culp J.S., Hellmig B., Woolf D.J., Debouck C., Harrison S.C. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc. Natl Acad. Sci. USA. 92:1995;1222-1226
30. Schinazi R.F., Larder B.A., Mellors J.W. Mutations in retroviral genes associated with drug resistance. Int. Antiviral News. 5:1997;129-142
31. Staszewski S., Miller V., Rehmet S., Stark T., De Cree J., De Brabander M., Peeters M., Andries K., Moeremans M., De Raeymaeker M., Pearce G., Van den Broeck R., Verbiest W., Stoffels P. Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients. AIDS. 10:1996;F1-F7
32. Tantillo C., Ding J., Jacobo-Molina A., Nanni R.G., Boyer P.L., Hughes S.H., Pauwels R., Andries K., Janssen P.A.J., Arnold E. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase implications for mechanisms of drug inhibition and resistance. J. Mol. Biol. 243:1994;369-387